Manufacturing, Cell Therapies
Industry Outlook 2025: Cell Therapy Advancement
April 10, 2025
The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about the bio/pharmaceutical trends from 2024 that continue to impact the industry in 2025.
Pharma 4.0: What are Industry Leaders Prioritizing in the Modernization of Pharmaceutical Manufacturing?
April 03, 2025
The move towards “pharma 4.0” requires a major shift, both ideologically and technologically, to adapt current processes to a framework that will automate much of today’s manufacturing.
Novartis’ Steady Investments in Slovenia Result in New Viral Vector Manufacturing Facility and a Growing Work Force
March 27, 2025
With a completed €40 million (US$43 million) investment in Slovenia, Novartis has opened its first specialized viral vector production facility in Europe, following earlier significant investments in R&D that has led to the growth of Slovenia’s workforce.
Behind the Headlines Episode 12–Cell and Gene Therapies, New Genomics Tools, and Recent Partnerships
March 05, 2025
Brian Feth, Xcell Biosciences; Thomas Heathman, Ori Biotech; and Matthew Lauber, Waters Corporation go behind the headlines and discuss commercialization challenges in the cell and gene therapy space; advances in new genomics tools from Roche, Illumina, and Eikon; and the latest development and manufacturing partnerships.
Behind the Headlines: Sana’s Type 1 Diabetes Breakthrough, Drug Price Negotiations, and More
January 27, 2025
Brian Feth, Jonathan Grinstein, PhD, Beth Willers, and Laks Pernenkil go behind the headlines to discuss major news announcements made during the JP Morgan Healthcare Conference, a wave of new Medicare drug price negotiations, and more.
Trenchant BioSystems Partners with Autolomous to Form Integrated Automated CGT Manufacturing Platform
January 24, 2025
The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days.
Cytiva Collaborates with Cellular Origins to Deliver Automated Manufacturing for CGTs
January 22, 2025
Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.
Scribe Reports Milestone for In Vivo Program Collaboration with Sanofi
January 14, 2025
Although specifics about the milestone were not immediately provided, Scribe is eligible to receive more than $1.2 billion for certain research, development, regulatory, and commercial benchmarks.
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
January 13, 2025
The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Behind the Headlines: Pandemic Preparedness, Novel mRNA Applications, and More
December 03, 2024
Edwin Stone, Bernard Sagaert, and Khaled Yamout go behind the headlines to discuss what the ongoing measles outbreak in the UK means for pandemic preparedness and anti-vaccination trends; new mRNA approaches; and what Roche’s acquisition of Poseida means for complex cell therapies.